Drug Trial Radar · NCT06568094
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 25, 2024
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
Conditions
- Prostate Cancer
Interventions
HRS-5041 tabletsDrug
HRS-5041 tablets
Abiraterone Acetate tablets(II)Drug
Abiraterone Acetate tablets(II)
Prednisone Acetate tabletsDrug
Prednisone Acetate tablets
Docetaxel InjectionDrug
Docetaxel Injection
HRS-1167 tabletsDrug
HRS-1167 tablets
SHR2554 tabletsDrug
SHR2554 tablets
HRS-6208 capsulesDrug
HRS-6208 capsules
HRS-2189 TabletsDrug
HRS-2189 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (Phase Ib)Time frame: 21 or 28 days
- Incidence and severity of adverse events (AE) (Phase Ib)Time frame: 2 years
- PSA response rate (Phase II)Time frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.